Actively Recruiting
New 3D-echocardiography-based Motion Integration and Management for Substrate Characterisation and Stereotactic Arrhythmia Radioablation Therapy in Ventricular Tachycardias - the MATRIX-VT Study
Led by University of Luebeck · Updated on 2024-08-29
20
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
Sponsors
U
University of Luebeck
Lead Sponsor
I
Institute for Robotics and Cognitive Systems, University of Luebeck, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting a prospective, observational pilot study at a single center to explore how artificial intelligence can integrate motion and structural data in patients with ventricular arrhythmia. The goal is to improve understanding of the arrhythmogenic substrate and enhance motion management during stereotactic arrhythmia radioablation therapy. This study focuses on patients undergoing catheter ablation for ventricular arrhythmia and uses advanced imaging techniques to gather data. The study analyzes data from preprocedural contrast-enhanced cardiac computed tomography and optically-tracked 3D transthoracic echocardiography. These imaging results from patients indicated for catheter ablation are processed using artificial intelligence to better characterize the ventricular arrhythmogenic substrate. The AI also aims to improve how the treatment area is defined for stereotactic arrhythmia radioablation by integrating motion data into planning. Participants with ventricular arrhythmia will have their imaging data collected and analyzed. Researchers will assess the feasibility of training AI algorithms to enhance substrate characterization and improve target volume planning for the radioablation therapy. Outcomes will be measured one month after complete data collection. The overall participation involves imaging procedures, AI data analysis, and follow-up to evaluate these technological integrations in treatment planning.
CONDITIONS
Brief Title
Echocardiography-based Motion Integration and Management for Substrate Characterization and STAR Therapy in Ventricular Tachycardias
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Indication for catheter ablation of ventricular arrhythmias including ventricular fibrillation, ventricular tachycardia, or premature ventricular contractions
- Indication for preprocedural contrast-enhanced cardiac computed tomography for cardiac structure characterization
You will not qualify if you...
- Platelet count less than 100,000 cells/mm3
- Body mass index (BMI) greater than 45 kg/m2 or less than 18 kg/m2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week before catheter ablation
Participants undergo preprocedural contrast-enhanced cardiac computed tomography and 3D transthoracic echocardiography to characterize cardiac structure and ventricular arrhythmogenic substrate.
1 to 2 visits depending on imaging requirements
Duration - Up to 1 month after data collection
Participants who undergo routine catheter ablation are observed, with data collected for analysis using artificial intelligence to improve substrate characterization and treatment planning.
Follow-up visits as part of routine care
Trial Site Locations
Total: 1 location
1
Klinik für Rhythmologie
Lübeck, Schleswig-Holstein, Germany, 23538
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here